Articles tagged with Alzheimer Disease
A review article reveals CD2AP's crucial role in amyloid metabolism, tau pathology, synaptic function, and neuroinflammation in Alzheimer's disease. CD2AP deficiency accelerates plaque formation, while its loss in neurons leads to reduced spine density and impaired synaptic plasticity.
A recent study published in The Journal of the Alzheimer's Association found that lecanemab, a new Alzheimer's-modifying drug, was less effective in female patients compared to males. The Phase 3 clinical trial showed a significant benefit in males, but little to no benefit in females, with the cause of the difference still unknown.
A study published in Nature Aging reveals that interleukin-12 (IL-12) plays a pivotal role in Alzheimer's disease progression, damaging mature oligodendrocytes and interneurons. By understanding this mechanism, researchers hope to develop new combination therapies.
A University of Minnesota research team has been awarded a $3.8 million grant to develop a new cell therapy targeting Alzheimer's disease. The project aims to adapt cancer treatment techniques to create specialized immune cells that can clear harmful proteins from the brain.
A new stem cell therapy trial at UTHealth Houston aims to reduce neuroinflammation in patients with presymptomatic Alzheimer's disease. The study, which is sponsored by Weston Brain Institute, will enroll 12 patients and use PET imaging to determine whether stem cells reduce brain inflammation before symptoms develop.
Researchers from UConn School of Medicine reveal a novel pathway in cellular dysfunction contributing to neurodegenerative diseases like Alzheimer's and ALS. They discovered that endothelial cells, the inner lining of blood vessels, play a critical role in neurodegeneration by disrupting the blood-brain barrier's protection.
Researchers found that individuals with lower acylcarnitine levels declined more slowly and showed fewer cognitive decline symptoms compared to those with high acylcarnitine levels. Healthy lifestyle interventions, such as a plant-based diet and exercise, may help lower bioenergetic age and potentially delay or prevent Alzheimer’s onset.
Researchers developed a portable system using AI to spot cognitive impairment by measuring subtle differences in motor function. The device accurately identified 83% of participants with mild cognitive impairment (MCI), offering potential for early intervention and improved outcomes.
The American Heart Association emphasizes the importance of brain health, citing a growing burden of dementia and neurological conditions worldwide. By adopting healthy behaviors and addressing modifiable risk factors, individuals can improve their cognitive function and reduce the risk of age-related decline.
A new Mass General Brigham study explores the connection between the Doomsday Clock and mortality and mental health in the United States, finding higher rates of Alzheimer's disease, suicide, and substance-related disorders at closer clock settings. The study suggests a potential bridge between global events and individual well-being.
Researchers have developed a computational tool, Spotiphy, that uses generative AI to enhance the resolution of sequencing-based spatial transcriptomics without sacrificing gene coverage. This breakthrough enables single-cell resolution in tissue imaging while maintaining full transcriptome coverage.
A new study analyzing global data from 1990 to 2021 found significant cross-country disparities in Alzheimer's disease and other dementias, with approximately two-thirds of individuals living in low- and middle-income countries. The study highlights the need for targeted prevention and control strategies in different countries.
Researchers at Scripps Research have synthesized a stable form of carnosic acid, which showed enhanced memory and synaptic density in mouse models of Alzheimer’s disease. The compound also decreased inflammation in the brain, offering potential as an anti-inflammatory drug for treating cognitive decline.
Researchers found that p-tau proteins in blood are elevated in both Alzheimer's and ALS patients, making them less specific for Alzheimer's diagnosis. However, they also show promise as potential biomarkers for early detection of ALS or monitoring disease progression.
A new Northwestern University study found that enhancing the brain's immune cells can clear Alzheimer's plaques and restore a healthier brain environment in immunized patient brains. The findings could reshape the future of Alzheimer's treatments by shifting the focus from removing plaques to harnessing the brain's natural defenses.
A new brain-mapping technique identified memory-related brain cells vulnerable to protein buildup, a key factor in Alzheimer's disease. The study found that certain cell types in the hippocampus and cortex were more affected by tau buildup.
A new Cochrane review has found evidence that music-based therapy may benefit people living with dementia, particularly by improving symptoms of depression. The review suggests that music therapy probably improves depressive symptoms and may improve overall behavioural problems by the end of treatment.
A study by Mass General Brigham researchers found that women over 70 who took hormone therapy had faster tau accumulation than those who didn't. This increase was seen in specific brain regions vulnerable to Alzheimer's disease. The findings suggest delaying hormone therapy may lead to worse Alzheimer's outcomes.
Researchers at USC Stem Cell discovered a gene called KCTD20 that suppresses glutamate toxicity, leading to enhanced tau protein clearance. This approach offers a promising therapeutic strategy for patients with tau-related neurodegenerative diseases, including Alzheimer's disease.
A study of nearly 900 postmenopausal women found an association between perimenopausal symptom burden and later cognitive function and behavioral impairment. Women with higher menopausal symptom burdens were more likely to experience poorer cognitive function and mild behavioral impairments, both markers of dementia.
Scientists repurposed the drug edaravone as an imaging probe to detect oxidative stress in brain tissue using PET scans. This technique can help diagnose neurological conditions such as ALS and Alzheimer's disease earlier, when treatment is more effective.
Researchers have discovered alarming levels of microplastics in human brain tissue, with concentrations 3-5 times higher in individuals with dementia diagnoses. The study highlights the need for large-scale human studies to determine dose-response relationships between microplastic exposure and chronic health outcomes.
Studies have consistently shown that 40Hz gamma stimulation can improve cognitive function and reduce Alzheimer's pathology in mice. In human clinical trials, participants exposed to 40Hz light and sound experienced significant slowing of brain atrophy and improvements on some cognitive measures compared to untreated controls.
A research team at the University of Cologne has identified a specific form of the tau protein, 1N4R, responsible for mediating toxic effects of protein clumps in human brain cells. This breakthrough understanding could lead to new treatments for Alzheimer's disease.
A unique case study reveals an unexpected discrepancy between Alzheimer's pathology and cognitive function in a woman with Down syndrome. The study highlights the need to expand inclusion criteria for therapeutic drug trials and uncover genetic or lifestyle factors that contribute to cognitive preservation.
Researchers discovered how air pollution and wildfire smoke can trigger S-nitrosylation of a key brain protein, preventing brain cells from making new connections. Blocking this chemical modification partially reversed signs of memory loss in Alzheimer's mouse models and nerve cells.
A team of scientists at Indiana University School of Medicine has identified a potential link between retinal changes and Alzheimer's disease. The study found that the APOE4 gene variant impairs retinal function in mice, suggesting a direct link to visual processing deficits associated with Alzheimer's disease.
A new blood test may help identify and monitor Amyotrophic Lateral Sclerosis (ALS), according to a recent study published in Neurology. The test uses neurofilament light chain proteins to accurately diagnose ALS, with an accuracy rate of over 80%.
A new study warns that blood tests for Alzheimer's disease are not reliable, particularly for Black patients. The test has lower sensitivity and specificity in Black participants, leading to a higher risk of false positives.
A multi-ancestry genome-wide study has identified 16 novel Alzheimer's disease-associated genetic signals, expanding the understanding of the disease in underrepresented groups. The study aims to improve predictions of Alzheimer's disease risk and guide new treatment targets for diverse populations.
A new University of Cincinnati trial is comparing two types of omega-3 supplements, LPC-DHA and TAG-DHA, to slow or prevent dementia progression in elderly adults. Researchers aim to investigate whether LPC-DHA supplementation increases CSF DHA levels and improves cognitive function.
A new study found that people from minority ethnic groups are more likely to report non-cognitive symptoms, such as pain and dizziness, before receiving a dementia diagnosis. This can lead to delays in diagnosis and impact health inequalities. The research aims to improve culturally fair recognition of possible dementia in primary care.
A new test called EpiAgePublic estimates biological age using only three DNA sites in the ELOVL2 gene, simplifying traditional methods while maintaining accuracy. The study found that EpiAgePublic accurately tracks aging patterns and can identify factors accelerating the aging process.
Researchers from Cleveland Clinic’s Genome Center linked human herpesviruses to Alzheimer's disease via transposable elements. They identified TEs activated in HSV-1 infected brains and found that commercially available drugs can reverse this pathway.
Only about 1 in 5 older Americans have undergone cognitive screening in the past year, highlighting a persistent barrier to diagnosis and treatment. Researchers emphasize the importance of early conversations about cognitive health to prevent progression and improve outcomes.
A new study reveals that asymptomatic neonatal HSV infections in mice can lead to persistent CNS infection and long-term cognitive decline. Maternal vaccination may prevent this cognitive impairment, suggesting a potential strategy for reducing neurological damage in infected offspring.
A comprehensive review published in Brain Medicine maps out the extensive influence of reproductive hormones on neurological health and disease. The study examines how sex hormones affect a broad spectrum of neurological conditions, including vascular disorders, movement disorders, epilepsy, multiple sclerosis, and Alzheimer's disease.
Researchers from Osaka University found that peristaltic pump action promotes amyloid nucleation in supersaturated fluids, including blood and cerebrospinal fluid. High shear stress caused by the pumping motion mechanically breaks supersaturation to induce amyloid formation.
Researchers explore the connection between Alzheimer's and metabolic syndrome, finding links between insulin regulation, high blood pressure, and obesity. The study suggests that maintaining healthy blood fat levels may be crucial for brain health, paving way for potential therapeutic developments.
A new remotely-delivered support programme, NIDUS-Family, has been shown to improve the lives of people with dementia while reducing healthcare costs. The programme uses goal setting and personalized care to help individuals live well at home for longer, resulting in cost savings of £8934 per person over one year.
Research reveals key differences in immune system response to Alzheimer's and bacterial infections, with larger Aeta clumps triggering more chronic inflammation.
A new blood test has shown promise in improving the accuracy of Alzheimer's Disease diagnosis, with results comparable to established CSF biomarkers. The study found that measuring plasma p-tau217 was over 90% accurate, potentially replacing invasive diagnostic methods for up to half of patients.
Researchers have identified changes in brain rhythms that indicate seizure activity in Alzheimer's patients. High-frequency oscillations (HFOs) occur at rates two to three times higher in Alzheimer's patients than in cognitively normal individuals.
Researchers at WashU Medicine found that new Alzheimer's therapies can add up to 10 months of independent living with lecanemab and 8 months with donanemab. The study provides a more meaningful measure of treatment benefits, focusing on day-to-day impacts on patients' lives.
Researchers at the University of Florida have discovered a novel genetic mutation associated with an accumulation of toxic proteins in Alzheimer's brains. The study found that people carrying a specific variation of this repeated DNA strand have more than double the risk of developing late-onset Alzheimer's.
FAIR Health introduces a new shared decision-making tool for Alzheimer's disease, providing clinical information on self-care options and drug therapies. The tool also offers related cost information to support age-friendly care, available at no cost to users.
A study at Lund University found that brain trauma triggers Alzheimer's disease through vascular changes, challenging existing paradigms. The research team identified increased aggregation of amyloid-beta and vascular alterations in patients with traumatic brain injury.
Researchers from the University of Gothenburg have made a breakthrough in understanding the role of protein tau in Alzheimer's disease. By identifying specific amino acid modifications that occur before thread-like fibrils form, scientists hope to develop complementary drugs to combat the disease.
Researchers developed a biomarker test that can detect small amounts of tau protein and its misfolded forms in cerebrospinal fluid, correlating with cognitive decline severity. The test identifies early stages of tau tangle formation up to a decade before brain scans, opening doors for early-stage disease diagnosis and intervention.
Researchers identified a link between Alzheimer's disease, cell function, and cholesterol in the brain. Lowering oxysterol levels freed trapped ABCA1, restoring its healthy state, and showed potential as a new treatment approach.
A Michigan Medicine-led study suggests that living in disadvantaged communities may decrease the length of time a person can survive with amyotrophic lateral sclerosis (ALS) by up to 37%. The study found that patients from more resourced areas tended to live longer, possibly due to better access to care and reduced caregiver burnout. T...
Researchers have uncovered a mitochondrial process that supports brain cells critical for learning, memory, and social recognition. The study reveals the critical role of the mitochondrial calcium uniporter in enabling neurons to strengthen connections through synaptic plasticity.
Researchers at Arizona State University propose a unifying explanation for Alzheimer’s disease, focusing on the role of chronic stress granules in disrupting gene activity. The condition causes massive changes in gene expression, affecting every known neuropathology and clinical manifestation.
Researchers discover that tau protein and beta-amyloid, key pathological hallmarks of Alzheimer's, affect brain circuits in distinct yet synergistic ways. This study suggests a potential breakthrough in treatment strategies by highlighting the need for dual-targeted therapies.
Certain mouth bacteria may support better memory and attention, while others increase the risk of Alzheimer's disease. The study found that an imbalance between beneficial and harmful bacteria can reduce nitric oxide production, crucial for brain communication.
Bess Frost, director of Brown University's Center for Alzheimer’s Disease Research, received the 2025 Rainwater Prize for her groundbreaking findings on tau toxicity and retrotransposons. Her work may lead to new treatments for neurodegenerative diseases, including Alzheimer’s and tauopathies.
A new drug developed by the Centre for Addiction and Mental Health (CAMH) has shown significant promise in reversing memory loss in a mouse model of Alzheimer's disease. The drug, GL-II-73, selectively targets GABA receptors to restore brain function and repair damaged neural connections.
Scientists from DZNE found that preventing brain inflammation may help treat Alzheimer's disease. The study, published in Immunity, suggests that inhibiting the NLRP3 inflammasome can reduce neuroinflammation and help microglia clear harmful amyloid-beta deposits.
The Primary Prevention Trial aims to determine whether stopping early molecular changes can prevent Alzheimer's disease from taking hold. The study will enroll people as young as 18 with few or no detectable Alzheimer's-related molecular changes in their brains.
A comprehensive genetic analysis of East Asian populations has identified key SORL1 genetic variants that confer protective effects against Alzheimer's disease. Individuals carrying these variants exhibited improved cognitive function, decreased neurodegeneration, and less severe AD pathology.